Previous close | 1.4300 |
Open | 1.4600 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.4300 - 1.5446 |
52-week range | 0.5350 - 2.8400 |
Volume | |
Avg. volume | 158,938 |
Market cap | 82.654M |
Beta (5Y monthly) | -0.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0800 |
Earnings date | 16 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.00 |
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-break
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD)Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asthma have been scheduled with the U.S. Food and Drug Administration (FDA) in Q2 2024 to discuss trial results and proposed registrational programsGranted Simcere the exclusive rights to develop, manufacture, and comme
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. W